Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-7 of 7 for your search:
Drug:
recombinant interferon alpha-2a
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 60
Sponsor:
Other
Protocol IDs:
DSMM V
, NCT00546988
2.
Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
3066K1-3311
, NCT00631371
3.
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ML19983
, NCT00520403
4.
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
12782
, EudraCT: 2007-005083-28, NCT00678288
5.
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab in Adult Patients With Kidney Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CRAD001L2201
, NCT00719264
6.
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
MO21609
, 2007-006611-23, NCT00796757
7.
Phase II Randomized Study of Dynamic Contrast-Enhanced MRI Assessment of Vascular Changes Induced With Bevacizumab Alone Versus in Combination With Recombinant Interferon Alpha-2a in Patients With Previously Untreated Stage III-IV Renal Cell Carcinoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
MTVERNHOSP-RD2007-114
, RD 2007-114, ENH-RD2007-114, EUDRACT-2008-006414-19, EU-20917, NCT00873236
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute